PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
Toronto, Ontario--(Newsfile Corp. - October 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical and technology company advancing pharmaceutical 3D printing for personalized medicine, today announced that it is building a portfolio of personalized peptide products for niche indications on its M3DICINES™ 3D-printed medicines platform, for near-term commercialization through the new U.S. peptide pathway. The first prod
Biotechnologies, Pharmaceutique
2026-10-29 10:01 AM EDT | PharmaTher Holdings Ltd.
BioHarvest Sciences to Report Third Quarter 2026 Financial Results on November 12, 2026
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its third quarter 2026 financial results before the market opening on Thursday, November 12, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to
Biotechnologies, Pharmaceutique, Santé
2026-10-29 8:00 AM EDT | BioHarvest Sciences Inc.
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
The oral small-molecule calpain inhibitor demonstrated meaningful visual acuity improvement in Phase 2 and Phase 3 CRAO studies conducted in Japan compared to controls. No therapeutics exist today to treat patients that experience CRAO vision loss. Kiora plans to advance KIO-401 (mitucapistat) into a multinational Phase 3 registration trial in CRAO, with initiation targeted for 2027. Company also plans to evaluate KIO-401 in a Phase
Biotechnologies, Pharmaceutique
2026-10-29 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Senior Canadian Officials and Diplomatic Leaders Tour the Self-Driving Lab Provided by Telescope Innovations to KPBMA in South Korea
Seoul, South Korea--(Newsfile Corp. - October 29, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), yesterday joined senior Canadian government and diplomatic leaders at the Korean Pharmaceutical and Biopharmaceutical Manufacturer's Association ("KPBMA") in Seoul to visit the facility's Self-Driving Lab. Installed by Teles
Technologies, Produits chimiques, Pharmaceutique
2026-10-29 1:49 AM EDT | Telescope Innovations Corp.
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
Highlights Two FDA designation applications submitted for creatine monohydrate in guanidinoacetate methyltransferase (GAMT) deficiency: Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD). First-in-class product opportunity. No FDA-approved treatment exists for GAMT deficiency. Families measure and mix high-dose creatine powder by hand, several times a day, for life. 3D printing for children. Weight
Biotechnologies, Pharmaceutique
2026-10-28 8:00 AM EDT | PharmaTher Holdings Ltd.
TempraMed Signs Exclusive Distribution Agreement with SPORTORO for Croatia, Serbia and Bosnia and Herzegovina
Highlights Definitive exclusive distribution agreement with SPORTORO d.o.o. for Croatia, Serbia and Bosnia and Herzegovina. Commercial scope covers VIVI Cap™, VIVI Epi™ and VIVI Med™, extending access across insulin pens, epinephrine auto-injectors, vials and other compatible temperature-sensitive medication formats. The agreement contemplates the initial order is to be placed and fully paid in
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-10-28 3:05 AM EDT | TempraMed Technologies Ltd.
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that it has retained LifeSci Advisors ("LifeSci" or "LifeSci Advisors") to support its investor relations and corporate communications activities. The engagement of LifeSci is being completed pursuant to t
2026-10-27 8:00 AM EDT | BetterLife Pharma Inc.
Herbal Dispatch Announces Results of Its 2026 Annual General and Special Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is pleased to announce the results of its annual general and special meeting of shareholders (the "Meeting") held on Monday, October 26, 2026. All matters put before the Meeting were approved by the requisite majority. Shareholders fixed the number of directors at three and elected Philip
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-10-27 6:00 AM EDT | Herbal Dispatch Inc.
InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed me
Biotechnologies, Pharmaceutique
2026-10-26 8:01 PM EDT | InMed Pharmaceuticals
Theralase Provides Bladder Cancer Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is providing an update on its Phase II Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Inva
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-10-26 7:00 AM EDT | Theralase Technologies Inc.
Unbuzzd Wellness Announces Closing of Private Placement Financing
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™, is pleased to announce that it has completed its non-brokered private placement financing (the "Offering") in two tranches for aggregate gross proceeds of $1,080,000 through the issuance of an aggregate of 5,400,000 common shares in the share capital of the Company (the "Shares") at a price of $0.20 per Share. The Company
2026-10-23 7:00 PM EDT | Unbuzzd Wellness Inc.
Defence Therapeutics Announces Convertible Debenture Interest Payment
Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company. The Company announces that, in accordance with the terms and condi
Biotechnologies, Pharmaceutique, Santé
2026-10-23 4:15 PM EDT | Defence Therapeutics Inc.
Global Hemp Group Appoints Mickey Goldstein as Chief Financial Officer, Appoints Davidson & Company as Auditor
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to announce the appointment of Mickey Goldstein, CPA, CA, as Chief Financial Officer, effective immediately. Ms. Goldstein succeeds Christopher Cherry. Ms. Goldstein is Director, Accounting Advisory at Crowe MacKay LLP, where she provides strategic financial and advisory services to priv
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Cannabis
2026-10-23 9:59 AM EDT | Global Hemp Group Inc.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce that, further to its news release dated September 28, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $600,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 5,200,000 units
Biotechnologies, Pharmaceutique, Santé
2026-10-22 5:24 PM EDT | PreveCeutical Medical Inc.
Telescope Innovations to Attend the 2026 Planet Microcap Investment Conference in Toronto
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), enabling technologies, and services for the global pharmaceutical and high-value chemical industries, today announced that members of its leadership team will attend the Planet MicroCap Toronto Investment Conference on Oc
Technologies, Produits chimiques, Pharmaceutique
2026-10-22 8:00 AM EDT | Telescope Innovations Corp.
Custom Health to Close the Market at the TSX on October 22, 2026, and Announces Appointments of Chief Commercial and Strategy Officer and Chief Compliance and Regulatory Officer
Custom Health will close the market at the Toronto Stock Exchange on October 22, 2026, to celebrate the Company's recent listing on the TSX Exchange. Mike Palackdharry has been appointed Chief Commercial and Strategy Officer, bringing more than 30 years of experience in commercial strategy, enterprise sales, business development, and strategic partnerships. Christina Garcia has been appointed Chief Compliance and Regulatory Officer, bringing more than 15
Technologies, Pharmaceutique, Santé
2026-10-21 6:00 AM EDT | Custom Health Holdings Inc.
TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
Recent Highlights: Record sales: July 2026 sales were about US$522K1, the best month in the company's history, and August was about US$403K, its second-best. Run rate revenue of ~US$5.5M Sales for the first eight months of 2026 were about US$2.07M, already above the US$1.8M booked for all of 2025. Growing patent portfolio: 4 new global patents granted in 2026, for a total of Global distribut
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-10-20 7:00 AM EDT | TempraMed Technologies Ltd.
Custom Health Highlights Early Results with BKC Pain Specialists, Supporting Expansion of Chronic Pain Program
Custom Health's existing commercial program with BKC Pain Specialists & Regenerative Medicine Clinic in Ohio is demonstrating early results through the integration of in-home medication technology, pharmacy services and pharmacist-led clinical support for patients managing complex chronic pain. The program provides continuous visibility into patients' medication use and experiences between physician visits, enabling personalized patient engagement, pharmacist-
Technologies, Pharmaceutique, Santé
2026-10-20 6:00 AM EDT | Custom Health Holdings Inc.
Herbal Dispatch Expands Offering with New Ontario and Saskatchewan Listings and Increased BC Portfolio
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today announced that four of its Happy Hour SKUs have been listed with the Ontario Cannabis Store ("OCS"). The Company also provided an update on its British Columbia and Saskatchewan distribution. ONTARIO LISTINGS
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-10-20 6:00 AM EDT | Herbal Dispatch Inc.
Richards Group Inc. Announces October 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - October 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended October 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on October 30, 2026 and will be payable on November 13, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether suc
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-10-19 11:36 AM EDT | Richards Group Inc.